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AS RECENTLY as the 1970s, patients played virtually no role in 
the U.S. Food and Drug Administration’s (FDA’s) process for approv-
ing drugs (Best 2012; Carpenter 2004). The drug development and 
review process was the exclusive domain of government bureaucrats, 
scientiﬁc experts, and the pharmaceutical industry. Not coincidentally, 
the agency provided desperately ill patients with access to promising 
investigational drugs only occasionally, on an ad hoc basis.
Today highly organized and well-funded patient advocacy groups 
regularly seek to inﬂuence FDA’s decisions regarding pharmaceutical 
products. The agency holds public meetings with patient advocates 
regarding drug development issues, includes them as “special govern-
ment employees” in private preapproval discussions with manufactur-
ers, and consults with them during internal agency review of drugs. 
Patients also regularly testify before FDA advisory committees, which 
often include a patient representative as a voting member. Both Con-
gress and FDA explicitly acknowledge the importance of the patient’s 
perspective with respect to risk–beneﬁt analyses, and they have estab-
lished programs to hasten the approval of important drugs and to 
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provide early access to desperately needed unapproved drugs. The 
Food and Drug Administration Safety and Innovation Act of 2012 
(FDASIA) reﬂects and requires this patient-centered ethos in various 
ways discussed in this chapter.
While the extent of patients’ actual impact on FDA decision making 
remains unclear, they irrefutably wield much more inﬂuence than they 
did four decades ago. This chapter explores a constellation of trends 
and events that underlie this dramatic shift, examines the current role 
of patients in drug regulation, and considers the future of patient-
focused drug development.
I. THE CULTURAL FOUNDATION
Various cultural developments of the past half century underlie the 
transformation of the American patient from a passive, uninformed 
recipient of medications into an active, knowledgeable participant in 
drug development and regulation.
A. The Decline of Trust
One critical trend has been the citizenry’s declining trust in the leaders 
of major institutions, including those that formerly exercised exclu-
sive control over the drug supply. This decay of conﬁdence has driven 
patients to intervene in the drug regulatory process rather than pas-
sively accept the decisions of governmental and scientiﬁc experts.
A loss of faith in large institutions and professional expertise was one 
of the deﬁning characteristics of the 1970s (Berkowitz 2006; Schul-
man 2002; Carroll 2000), and Americans have remained skeptical 
about the motives and competence of “the establishment” ever since. 
Between the mid-1960s and 1980, the percentage of poll respondents 
saying “you can trust” the leaders of various institutions plummeted 
with respect to all institutions considered, including the federal gov-
ernment, the medical profession, and major companies. Although the 
public’s conﬁdence has waxed and waned since 1980, its trust level has 
never approached its mid-1960s peak (Harrisinteractive.com 2011; 
Website of American National Election Studies). FDA appears to have 
maintained the public’s esteem longer than other institutions. Since 
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the turn of the twenty-ﬁrst century, however, conﬁdence in the FDA 
has fallen precipitously, as well (Carpenter 2010:12, 749–50).
B. The Rights Revolution
The 1970s have also frequently been identiﬁed as the period of the 
“rights revolution” (Berkowitz 2006:133–57; Sandbrook 2011:249–
50). Concepts like women’s rights, gay rights, environmental rights, 
disability rights, and consumer rights dominated the national conver-
sation. Another important aspect of the rights revolution that blos-
somed in the 1970s was the notion of “patients’ rights.” The genesis 
of the patients’ rights movement appears to have been the drafting in 
1970 of twenty-six such rights by the National Welfare Rights Orga-
nization. This action precipitated a widespread discussion that culmi-
nated in the adoption of a “Patient’s Bill of Rights” in 1973 by the 
American Hospital Association. This document, and indeed the entire 
patients’ rights movement, was premised on the notion that patients 
would no longer simply accept the ministrations of a presumptively 
wise and beneﬁcent medical system but would instead become active, 
informed agents in their own treatment. It is important to note that 
the patients’ rights movement overlapped in signiﬁcant ways with 
other rights movements—for example, those for disability rights, racial 
civil rights, women’s rights, and—most importantly for this chapter—
gay rights.
The rights culture and rhetoric that coalesced in the 1970s lived 
beyond it (Walker 1998:33). One author argues that the rights rev-
olution “survived the Reagan and Bush years unscathed and even 
enhanced” (Sandbrook 2011:250). This assertion is certainly true 
with respect to patients’ rights.
C. The Changing Health Information Environment
Another noteworthy cultural development of the past several decades 
is the enormous increase in health information available to the gen-
eral public. Although domestic health guides have existed through-
out American history, until quite recently publishers did not seek a 
mass market for books containing technical information about the 
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treatments administered and prescribed by physicians. This changed in 
1979, when Bantam released the ﬁrst edition of The Pill Book, subtitled 
The Illustrated Guide to the Most Prescribed Drugs in the United States. 
Seventeen printings of the ﬁrst edition totaled more than one mil-
lion copies. Competitors, including the American Medical Association, 
soon offered their own volumes with similar information. For consum-
ers not daunted by technical language, the Physicians’ Desk Reference, 
containing the full physician package insert for every approved drug, 
became widely available in bookstores shortly after The Pill Book and 
was an immediate bestseller (Fleischer 1981).
Today, of course, the signiﬁcance of printed books about prescrip-
tion drugs pales in comparison to that of the Internet, which has made 
it easy for anyone with a computer or smartphone to ﬁnd detailed 
medical information. During the 1990s, thousands of health-oriented 
sites appeared on the new World Wide Web. Commercial websites that 
organized this universe of information for consumers began appearing 
in the late 1990s. By 2007, 40 million unique users visited WebMD 
alone each month (Freudenheim 2007). Although advanced search-
engine technology has since reduced the importance of such websites, 
American patients remain voracious (and in many instances, sophisti-
cated) consumers of medical information (Duggan and Fox 2013).
Finally, patients today receive abundant information about pre-
scription drugs directly from the manufacturers. As explored in detail 
elsewhere (Grossman 2014), until the 1980s, the typical consumer 
never saw labeling or advertising for any prescription drug, with the 
possible exception of the patient package insert for oral contracep-
tives. FDA traditionally believed (in agreement with physicians and 
industry) that consumers of prescription medications should be 
ignorant and passive beneﬁciaries of their doctors’ care. However, 
a dramatic transformation in agency policies during the past several 
decades has led to a deluge of patient labeling and direct-to-consumer 
advertising of prescription drugs.
II. THE RISE OF FOOD AND DRUG ACTIVISM
The mass mobilizations of AIDS and breast cancer activists in the 
1980s are often identiﬁed as the pioneering models for modern patient 
activism (Carpenter 2004:58; Bix 1997). But even these movements 
lync17118_book.indd   62 23/04/15   9:38 am
FDA and the Rise of the Empowered Patient 63
had precedents—campaigns in the 1970s involving vitamin pills, sac-
charin, and Laetrile (an alternative cancer therapy). These earlier social 
movements, though not focused on conventional prescription drugs, 
demonstrated how organized citizens could successfully ﬁght to pre-
serve consumers’ freedom to make their own risk–beneﬁt judgments 
about FDA-regulated products.
In August 1973, FDA issued a rule restricting the permissible 
combinations of nutrients in vitamin and mineral supplements (38 
Fed. Reg. 20,723). The rule also declared that the agency would 
regulate high-potency supplements as drugs and, in some instances, 
prescription drugs. A health libertarian organization with right-wing 
propensities, the National Health Federation (NHF), was at the heart 
of the opposition, but the dissent blossomed into a genuine popular 
movement. The NHF choreographed a demonstration against “nutri-
tional tyranny” in Washington. Its alarmist (and inaccurate) warnings 
that “the Government is going to take our vitamins away” triggered 
what the New York Times characterized as a “massive ﬂow of letters” 
to Congress (Lyons 1973). Vitamin deregulation was, along with 
Watergate, the energy crisis, and the economy, one of the four issues 
that generated the most mail to Congress in 1973 (“Of Vitamins, 
Mineral: Fighting the FDA” 1974).
In 1974 testimony supporting Congressional intervention, the leg-
islative counsel for a health food industry trade group voiced a regula-
tory philosophy that seemed to reﬂect the views of a broad swath of 
Americans: “As long as he is not dealing with dangerous or untruth-
fully labeled food, then risktaking [sic] should be for each man to 
decide for himself…” (Senate Subcommittee on Health 1974). The 
next day, the U.S. Court of Appeals for the Second Circuit partially 
struck down FDA’s vitamin and mineral regulation (National Nutri-
tional Foods Ass’n v. FDA 1974:761). Two years later, Congress—
without a single dissenting vote—invalidated the remainder of the rule 
with the Vitamin-Mineral Amendments of 1976 (90 Stat. 401, 410).
Another mass protest against FDA arose in response to the agency’s 
April 1977 proposal to revoke the interim food additive approval for 
saccharin, which was then the only artiﬁcial sweetener on the market 
(42 Fed. Reg. 19,996). After studies demonstrated saccharin’s carci-
nogenicity in rats, the agency did not really have any discretion in the 
matter, for the Federal Food, Drug, and Cosmetic Act’s (FDCA’s) 
Delaney Clause states that “no additive shall be deemed to be safe 
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if it is found to induce cancer when ingested by man or animal” 
(21 USC § 409(c)(3)(A)). After publishing the proposed rule revok-
ing the approval, however, the agency reported that “the protest is 
stronger and louder than any response in recent history” (Winter 
1977). Outraged citizens included not only diabetics (and their physi-
cians), but also millions of people who drank diet soda to limit caloric 
intake. A Harris survey found that Americans opposed the saccharin 
ban by 76 percent to 15 percent (Harris 1977).
As it had in the vitamin-mineral supplement controversy, Congress 
stepped in. By an overwhelming margin, it enacted legislation in 1977 
to suspend FDA’s prohibition of saccharin while also mandating warn-
ings of its carcinogenicity in animals (91 Stat. 1451). Senator Edward 
Kennedy queried: “If a substance has both beneﬁts and risks, who 
should decide whether the risk should be taken—the Federal Govern-
ment or the individual?” (123 Cong. Rec. S29352 (Sept. 15, 1977)). 
He concluded, in light of saccharin’s undoubted beneﬁts and the divi-
sion of opinion regarding its safety, that “the individual is in the best 
position to decide for himself or herself whether they [sic] want to 
expose themselves or their children to saccharin use.”
At about the same time, the ﬁrst-ever mass protest against FDA’s 
refusal to permit marketing of a drug was gaining momentum. The 
product at issue was Laetrile (amygdalin), an alternative cancer treat-
ment derived from apricot pits. Although Laetrile advocacy was for-
merly conﬁned largely to right-wing extremists, the 1972 arrest of 
a California doctor who prescribed Laetrile “launched a signiﬁcant 
SM [social movement]…as people from across the political spec-
trum united under the libertarian banner of medical freedom” (Hess 
2005:522).
In May 1977, FDA held court-ordered public administrative hear-
ings to resolve questions regarding Laetrile’s legal status. These hear-
ings, jammed with rowdy Laetrile supporters, took on an almost riotous 
atmosphere (Young 1992:224; “Laetrile Backers, Foes Clash at FDA 
Hearing” 1977). Meanwhile, U.S. Representative Steven D. Symms, 
citing “grass roots support” stemming from outrage over the Laetrile 
situation, was promoting his “Medical Freedom of Choice Bill” (H.R. 
54; “Legalize Laetrile as a Cancer Drug? Interview with Represen-
tative Steven D. Symms” 1977). This law would have repealed the 
power FDA acquired in 1962 to review the efficacy as well as the 
safety of new drugs before marketing. The Symms bill gained at least 
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110 cosponsors in the House of Representatives (123 Cong. Rec. 
18752 (June 13, 1977)). The Washington Post opined that the Lae-
trile matter was “already out of [the] control” of the “professionals” 
and “bureaucrats” (Editorial 1977). Even the editor of the New Eng-
land Journal of Medicine suggested that FDA legalize Laetrile to calm 
the “Laetrilomania” (Ingelﬁnger 1977).
In July 1977, a poll showed that 58 percent of Americans believed 
Laetrile should be sold legally, versus 28 percent who opined that it 
should remain illegal (The Roper Organization 1977). In response 
to boisterous state legislative hearings and torrents of mail to law-
makers, half of the states passed Laetrile legalization statutes (Young 
1992:221). The public’s interest in the drug faded in the early 1980s 
(Young 1992:232–33), and the Laetrile campaign ultimately had no 
direct effect on federal food and drug regulation. Nonetheless, the Lae-
trile supporters showed how patient advocacy movements could shake 
FDA to its foundations—an important lesson for their successors, the 
AIDS activists.
III. AIDS ADVOCACY
With the terrifying spread of AIDS in the 1980s, groups such as ACT 
UP, Project Inform, and the Gay Men’s Health Crisis commenced an 
epic, ultimately successful struggle to shape FDA’s decisions regarding 
drugs for the disease (Arno and Feiden 1992; Carpenter 2010:428–
57; Epstein 1996; Hilts 2003:236–54).
In 1986, under pressure from AIDS groups, FDA made the unap-
proved investigational drug AZT available to patients outside of for-
mal clinical trials on a “compassionate use” basis. The next year, FDA 
approved the new drug application (NDA) for AZT, despite the absence 
of large Phase 3 clinical investigations and experts’ doubts regarding 
its safety and effectiveness. Less than two years elapsed between the 
submission of AZT’s investigational new drug (IND) application and 
its NDA approval—an astonishingly brief period compared to most 
drugs. On the very same day in 1987 that FDA approved AZT, it fur-
ther responded to AIDS activists’ demands by proposing a “Treatment 
IND” rule (52 Fed. Reg. 8850). This regulation, ﬁnalized two months 
later (52 Fed. Reg. 19466), permitted seriously ill people lacking sat-
isfactory alternatives to gain access to investigational drugs that “may 
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be effective,” although this access was strictly limited to ensure that the 
drugs would also be tested in controlled clinical studies.
Despite these successes, the AIDS interest groups’ victory was far 
from complete. Later in 1987, an FDA advisory committee recom-
mended against approving the NDA for ganciclovir, a promising treat-
ment for a blindness-inducing viral infection common among people 
with AIDS. The AIDS groups, outraged by the committee’s recom-
mendation, threatened action. They became even more furious when 
FDA imposed extremely strict access restrictions on the treatment 
IND for another drug, trimetrexate. Following stormy congressional 
hearings, FDA surrendered and broadened the terms of the trimetrex-
ate IND.
AIDS activists nonetheless feared that the agency would remain an 
obstinate barrier to early access to promising drugs. In September 
1988, ACT UP conducted a highly publicized symbolic takeover of 
FDA headquarters in suburban Maryland, protesting the agency’s 
approach to ganciclovir, trimetrexate, and other treatments. The 
handbook for the action declared: “The FDA says it exists to protect 
consumers. Well, people with HIV are consumers too, and they need 
to be protected from a deadly disease” (Eigo 1988).
After this demonstration, FDA seemed more responsive to the con-
cerns of AIDS patients. Just eight days after the takeover, the agency 
promulgated an interim regulation, “Subpart E,” which facilitated faster 
development and approval of drugs for life-threatening and severely 
debilitating diseases. Subpart E did so by guaranteeing drug compa-
nies early consultation on study design, authorizing NDA approvals 
based solely on Phase 2 trial results, and implementing a more ﬂexible 
risk–beneﬁt analysis that considered “the severity of the disease and the 
absence of satisfactory alternative therapy” (21 CFR 312 Subpart E, 
§ 312.84(a)).
The activists’ success in inﬂuencing FDA policy became further 
apparent in connection with ddI, a drug closely related to AZT. In 
response to continuing pressure from the AIDS community, FDA 
embraced a “parallel track” approach to ddI, allowing patients who 
did not qualify for the ongoing Phase 2 trials of the drug to take it 
for treatment purposes if AZT did not help them. In 1989, AIDS 
activists, with the assistance of FDA and National Institutes of Health 
(NIH) officials, persuaded ddI’s manufacturer to make the drug avail-
able at no cost to these patients. FDA soon officially embraced the 
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“parallel track” mechanism more generally (55 Fed. Reg. 20856 
(May 21, 1990); 57 Fed. Reg 13250 (April 15, 1992)). Moreover, 
in 1991, the agency approved the NDA for ddI before the comple-
tion of the Phase 2 trials, based on data showing efficacy in achieving 
surrogate endpoints (rather than longer survival). The next year, FDA 
formalized this approach, as well, when it promulgated its Accelerated 
Approval (“Subpart H”) regulations, which permit the approval of 
drugs for serious or life-threatening illnesses based on their effect on 
unvalidated surrogate endpoints reasonably likely to predict clinical 
beneﬁt (21 CFR 314 Subpart H).
Congress subsequently incorporated many of the AIDS move-
ment’s demands into the FDCA itself. The Food and Drug Admin-
istration Modernization Act of 1997 (FDAMA) (111 Stat. 2296) 
codiﬁed FDA’s Treatment IND rule, the Subpart E regulations (under 
the rubric “Fast Track”), and an expanded version of the Accelerated 
Approval rule (21 USC §§ 356, 360bbb).
IV. BEYOND AIDS
The reform of FDA’s drug approval system was only one of the AIDS 
movement’s visible triumphs in the late 1980s and early 1990s. It 
also effectively lobbied NIH and Congress for dramatic increases in 
federal funding for research into the disease (Bix 1997:781). Other 
disease communities noticed the AIDS activists’ achievements (along 
with breast cancer advocates’ contemporaneous success in garnering 
federal research funds), and a spectacular proliferation of patient advo-
cacy organizations occurred. Whereas some of these organizations 
were funded by the pharmaceutical industry, others represented only 
the interests of disease victims. The number of large, disease-focused 
nonproﬁts swelled from 400 at the beginning of the 1990s to more 
than 1000 in 2003 (Best 2012:781).
Today, following the model forged by the AIDS community, these 
disease groups regularly seek to sway FDA drug approval decisions. 
FDA advisory committee meetings, once technical affairs attended 
solely by scientists, bureaucrats, lawyers, and corporate officials, are now 
sometimes crowded with representatives of disease advocacy organiza-
tions, some of whom offer impassioned testimony. Moreover, patient 
advocates now often serve on the advisory committees themselves. 
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Their presence is another legacy of the AIDS movement. In 1991, in 
response to activists’ demands, FDA created a position for a patient 
representative on the Antiviral Drugs Advisory Committee for HIV 
(Food and Drug Administration 2015). Inspired by this development, 
cancer organizations asked for similar representation on committees 
reviewing cancer-related therapies, and the Clinton Administration 
granted this request in 1996 (Clinton & Gore 1996:9).1
Patients are now important and visible actors in the advisory com-
mittee process. Consider, for example, a September 2012 meeting of 
the Oncologic Drugs Advisory Committee concerning the neoadju-
vant breast cancer drug Perjeta. Participants in the open public hear-
ing session included both individual survivors and representatives of 
Facing Our Risk of Cancer Empowered (FORCE) and Breastcancer.
org (Food and Drug Administration 2013a). The committee itself 
included a voting patient representative, Debra Madden, a two-time 
cancer survivor. The advisory committee ultimately voted unani-
mously in favor of granting accelerated approval to Perjeta for patients 
with early stage breast cancer before surgery, and FDA followed this 
recommendation.
It is difficult to assess precisely how inﬂuential patient activities were 
to this and other NDA approvals. But in a few prominent instances, 
patient activism has unambiguously changed outcomes. For example, 
in response to protests by sufferers of irritable bowel syndrome, in 
2002 FDA permitted the return to the market of Lotronex, a drug pre-
viously withdrawn because of occasional severe side effects. Moreover, 
statistical analyses, along with anecdotal and observational evidence, 
indicate that effective political and media campaigns by patient groups 
shorten FDA drug review times (Carpenter 2004:59–60). Further-
more, the accelerated approval and fast track procedures, which owe 
their very existence to patient activism, have been extremely useful in 
getting needed treatments to desperate patients more quickly.
Another indication of FDA’s growing patient orientation in drug 
development is the agency’s creation, in cooperation with the Critical 
Path Institute and the pharmaceutical industry, of a Patient-Reported 
Outcome (PRO) Consortium. This public-private initiative’s mis-
sion—to evaluate and qualify PRO instruments for use as endpoints 
in clinical trials—is premised on the understanding that “[m]ore and 
more, it has been recognized that some assessments [of investigational 
medical products] might best be made by the patients themselves” 
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(Food and Drug Administration 2010). The consortium has held 
annual workshops since 2010.
The impact of patient activism on FDA regulation of drugs should 
not be overstated. For example, treatment INDs remain rare. Although 
this scarcity is due primarily to manufacturers’ reluctance to participate 
in early access programs and not to any FDA hesitancy to authorize 
them (Groopman 2006),2 one reason for the industry’s lack of enthu-
siasm is the severe restrictions the agency imposes on charging for 
investigational drugs (21 CFR 312.8). In 2007, these restrictions sur-
vived a constitutional challenge brought by a patient advocacy group 
in the U.S. Court of Appeals for the District of Columbia Circuit 
(Abigail Alliance 2007).
Nevertheless, the patient activists of the 1980s and 1990s undeni-
ably drove FDA to reconceive the essence of its mission. The agency 
embraced the task not only of protecting the public health by prevent-
ing the sale of dangerous products, but also of enhancing the public 
health by ensuring rapid access to useful remedies (Arno & Feiden 
1992:109). In 1997, Congress amended FDA’s official mission state-
ment to reﬂect this shift—listing health promotion before health pro-
tection (21 USC § 1003(b)).
A. Food and Drug Administration Safety  
and Innovation Act of 2012
The Food and Drug Administration Safety and Innovation Act of 
2012 (126 Stat. 993) represents a further advance in the rise of a 
patient-centered ethos, especially in the way the statute mandates 
patient involvement in earlier stages of the drug development process. 
FDASIA adds a new section 569C to the FDCA, titled “Patient Par-
ticipation in Medical Product Discussion” (21 USC § 360bbb-8c). 
This section obligates FDA to “develop and implement strategies to 
solicit the views of patients during the medical product development 
process and consider the perspectives of patients during regulatory 
discussions.” To this end, it speciﬁcally instructs FDA to encourage 
the participation of patient representatives in agency meetings with 
the sponsors of drug, device, and biologic applications. In addition, 
FDASIA adds a new “breakthrough therapy” designation to expe-
dite development of drugs that may offer substantial improvement 
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over existing therapies, expands the situations in which accelerated 
approval is available, and broadens the surrogate endpoints on which 
such approval can be based (21 USC §§ 356(a), (c)).
FDASIA has prompted FDA to embrace a broad initiative titled 
“Patient-Focused Drug Development.” Title I of FDASIA, the Pre-
scription Drug User Fee Amendments of 2012, binds FDA to detailed 
performance goals for 2013 through 2017 set forth in a separate doc-
ument (126 Stat. 993, 996). The goals enunciated by FDA in this 
document promise to move patients ever closer to the center of fed-
eral drug regulation. Under the heading of “Enhancing Beneﬁt–Risk 
Assessment in Regulatory Decision-Making,” FDA commits not only 
to increasing its use of patient consultants in regulatory discussions 
about speciﬁc products but also to holding four meetings per year 
with patient advocates regarding various disease areas (Food and Drug 
Administration 2013b). In its September 2013 notice of this series 
of meetings, FDA explained: “Patients who live with a disease have a 
direct stake in the outcome of the review process and are in a unique 
position to contribute to weighing beneﬁt–risk considerations that can 
occur throughout the medical product development process” (77 Fed. 
Reg. 58848, 58849).
As part of its patient-centered initiative, FDA has launched a pro-
gram called the “FDA Patient Network” (Food and Drug Admin-
istration 2015). Among other functions, this program educates 
consumers about the development and approval of medical products, 
announces advisory committee meetings, provides information about 
clinical trials and early access programs, and recruits volunteers to 
serve as patient representatives on advisory committees and within 
the product review divisions.
V. THE FUTURE
Further integration of patients into drug regulation presents both 
opportunities and challenges for FDA. Such measures are likely to 
boost the agency’s reputation and public support, as they did in the 
1980s and 1990s (Carpenter 2010:398). But any respect and good 
faith so earned could quickly dissolve if the agency’s eagerness to sat-
isfy the demands of sympathetic patients were to result in a postap-
proval, Vioxx-type safety ﬁasco. FDA can mitigate this risk, however, 
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through liberal and creative use of its power to approve drugs subject 
to a Risk Evaluation and Mitigation Strategy (REMS). FDA might 
also face continuing pressure from patient groups to tweak its early 
access programs to entice more manufacturers to participate in them—
perhaps by revisiting the current limits on charging for investigational 
drugs (21 CFR 312.8). But if these programs become more widely 
used, FDA may struggle to preserve the integrity of pivotal controlled 
clinical trials. Overall, the agency may struggle to simultaneously sat-
isfy patients and maintain its standing as the planet’s “gold standard” 
gatekeeper for new drugs.
In addition, FDA must consciously strive to avoid devoting a dispro-
portionate share of its limited resources to diseases endemic to popu-
lations with the wherewithal to support the most effective advocacy 
organizations. The AIDS movement was successful in part because it 
was dominated by a corps of middle-class, highly educated white men 
with experience in social movement tactics (Epstein 1996:12). Not all 
disease groups have these advantages. And the AIDS crisis notwith-
standing, prioritizing a disease because it happens to be represented 
by well-funded and skillful advocates may be both unwise and unjust 
(Dresser 2001:79–83). Furthermore, FDA should not assume that 
the leaders of disease organizations necessarily represent their entire 
diverse constituencies (Dresser 2001). Finally, the agency should care-
fully assess the extent to which any particular disease group represents 
independent interests rather than those of industry backers.
Patient groups trying to shape drug regulation face challenges, too. 
First, they increasingly must reckon not only with FDA and NIH but 
also with the Center for Medicare and Medicaid Services (CMS). As 
the number of insured Americans rises, the coverage decisions of CMS 
are having a growing impact on patient access to particular drugs. 
Accordingly, patient activists are focusing more energy on this agency. 
For example, in 2011, patient mobilization helped induce CMS to 
pledge to continue covering Avastin for breast cancer after FDA with-
drew approval of the drug for that use. And in light of “stakeholder 
input”—including furious protest by patients—CMS in 2014 with-
drew a proposal to allow formulary limitations in Medicare Part D 
coverage for three classes of drugs (Pear 2014).
Another challenge to patient organizations arises from the increas-
ing speciﬁcity of illness and treatment resulting from medical advances, 
particularly in genetics. What will happen to today’s disease-based 
lync17118_book.indd   71 23/04/15   9:38 am
72 FDA in a Changing World
groups if growing knowledge about disorders, together with the rise 
of gene-based personalized medicine, fractures the unity, and per-
haps even the coherence, of current disease classiﬁcations? Consider, 
for example, ﬁbromyalgia and chronic fatigue syndrome—diseases of 
unknown, and perhaps variegated, etiologies. Each has its own national 
patient advocacy association, and each was the topic of one of the 
ﬁrst “patient-focused drug development” meetings held by FDA. But 
one can easily imagine a future in which these syndromes disintegrate 
into multiple, distinct subtypes, each with its own organization. The 
path from the American Cancer Society (1913) to the Leukemia & 
Lymphoma Society (1949) to the Lymphoma Foundation of America 
(1986) to the Cutaneous Lymphoma Foundation (1998) presents a 
model that, if expanded throughout the world of morbidity, could 
result in uncoordinated activism and intergroup competition. Disease 
advocacy groups, which have long shared certain overarching goals 
with respect to FDA policy, may start ferociously competing with each 
other for the agency’s resources and attention the way they already vie 
for NIH funds.
Even as they confront these challenges, however, patients are 
unlikely ever to lose their hard-earned inﬂuential role in American 
drug regulation.
NOTES
This work is derived in part from an article previously published in the Admin-
istrative Law Review: Lewis A. Grossman. 2014. “FDA and the Rise of the 
Empowered Consumer.” Administrative Law Review 66: 627–77.
1. FDA gave these representatives full voting privileges later that year 
(Food and Drug Administration 2015).
2. In 2014, FDA stated that it had approved 99 percent of all expanded 
access requests since October 2009 (Silverman 2014).
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